Autolus Therapeutics plc (NASDAQ:AUTL) shares have surged 26.5% after a fund managed by Blackstone, Blackstone Life Sciences, agreed to invest up to $250 million in the company.
AUTL Stock Analysis - [Full Report] AUTL Chart by TradingView. Shares of Autolus Therapeutics (NASDAQ: AUTL) surged 25% on Monday after the biopharmaceutical company struck a deal to receive financing of up to $250 million from Blackstone Life Sciences. The company's clinical-stage pipeline comprises five. The Autolus Therapeutics plc stock price fell by -3.71% on the last day (Wednesday, 17th Nov 2021) from $7.00 to $6.74.During the day the stock fluctuated 5.65% from a day low at $6.73 to a day high of $7.11.The price has fallen in 6 of the last 10 days, but is still up by 13.28% over the past 2 weeks. Nov-30-20 07:00AM. Good News For Autolus Therapeutics plc (NASDAQ:AUTL): Stock Could Go Up 332.1% More stocksregister 5/19/2021. In order for the stock price to hit the forecast high, the stock would need to plunge -361.29% from its current level, while the stock would need to crash -15.32% from its current level to reach the projected low. The analysts previously had rating of Hold. Or you can just type "AUTL news" to get the latest stock news. Morningstar Rating. Shares of Autolus Therapeutics plc (NASDAQ: AUTL) jumped about 30% in premarket trading on Monday after it said Blackstone Life Sciences agreed to invest up to $250 million to fund the development of its new therapy for Leukemia. Or you can just type "AUTL news" to get the latest stock news. Autolus Therapeutics plc (NASDAQ:AUTL) - Stock analysts at William Blair upped their FY2021 EPS estimates for shares of Autolus Therapeutics in a research note issued to investors on Monday, November 8th. Based on 5 analysts giving stock ratings to Autolus Therapeutics in the past 3 months Analyst Price Target on AUTL $15.40 (107.27% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Autolus Therapeutics in the last 3 months. Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. AUTL. Blackstone triggers a 30% increase in Autolus Therapeutics shares. Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. The London Stock Exchange does not disclose whether a . Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. Sep 02, 2021. AUTL 6.11 0.32 (4.98%) Post-Market 0.05 (0.82%) 2,821. LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2021 financial results and operational highlights before open of U.S. markets on Wednesday, November 3, 2021.
LONDON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced. Autolus Therapeutics plc (AUTL) saw an uptrend of 5.24% in the recent trading with $6.43 being its most recent. The post Blackstone triggers a 30% increase in Autolus Therapeutics shares appeared first on Invezz. Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine. The average price target is $14.67, with a high forecast of $21.00 and a low forecast of $9.00. Find real-time AUTL - Autolus Therapeutics PLC stock quotes, company profile, news and forecasts from CNN Business. AUTL Stock Predictions, Articles, and Autolus Therapeutics Plc ADR News From the Web Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge Autolus Therapeutics to participate in upcoming virtual investor conferences. You'll get all this info in one place. Sep 02, 2021. Outlook Therapeutics Downgraded by Zacks Investment Research on 10/19/2021. Autolus Therapeutics published a press release on Nov. 8, announcing Blackstone Life Sciences to invest up to $250 million in AUTL for funding the development of new treatment for a serious form of leukemia. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. AUTL Stock Forecast - Is AUTL a buy or sell? Sep 16, 2021. In June 2021, Autolus Therapeutics had US$216m in cash, and was debt-free. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly . Looking to buy or sell Autolus Therapeutics (AUTL)? Autolus Therapeutics PLC (NASDAQ: AUTL) surged over 29% in premarket trading after Blackstone Life Sciences signed on to provide the company up to $250 million in equity and product financing. News. . Interested in getting the full scoop on AUTL, including earnings and dividends, stock forecast, buy or sell analysis and key stats? During the day the stock fluctuated 5.65% from a day low at $6.73 to a day high of $7.11. Volume has increased on the last day by 56 thousand shares but on falling prices. Autolus Therapeutics to Present New Data on AUTO1 in r/r Indolent B Cell Lymphomas at .
News. Free Signup: Advanced stock screener. Syncona said Blackstone Life Science will invest $250 million in Autolus. Quote Stock Analysis News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating . The current price level -47.42% lower than the highest price of $12.23 marked by the stock while trading over the past 52-weeks, whereas it is 39.78% higher than the lowest price of $4.60 the company dropped to over past 52-weeks. $150 million out of the total . The Autolus Therapeutics plc stock price fell by -3.71% on the last day (Wednesday, 17th Nov 2021) from $7.00 to $6.74. View Autolus Therapeutics AUTL investment & stock information. (67.8% per year) is forecast . If so, you came to the right place. Of the total . Autolus Therapeutics says that this includes its "CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as next generation product therapies of. News. That average rating earns the stock an Analyst Ranking of 80, which means it ranks higher than 80 of stocks, based on data compiled by InvestorsObserver. The price target was set to $6.05+13.7%. Sep 15, 2021. Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors. Blackstone Life Sciences has also agreed to purchase $100 million of Autolus Therapeutics plc (NASDAQ:AUTL)'s stock. The company operates in two geographic regions, the United Kingdom and the United States. Autolus Therapeutics Forecast Models Autolus Therapeutics time-series forecasting models is one of many Autolus Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Over the next 52 weeks, Autolus Therapeutics PLC has on average historically fallen by 41.6 % based on the past 3 years of stock performance. You'll get all this info in one place. In the last year, its cash burn was US$154m.
Learn about the latest financial forecast of XRTX. The latest Autolus Therapeutics Ltd ADS Each Rep 1 Ord Shs share price. Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. 1 week ago - GlobeNewsWire Autolus Therapeutics announces publication describing its small molecule-regulated CAR T cells LONDON and CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell . The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. Get the latest Autolus Therapeutics AUTL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.
So it had a cash runway of approximately 17 months from June 2021. Looking to buy or sell Autolus Therapeutics (AUTL)? Autolus Therapeutics plc - ADR Forecast, Short-Term " AUTL" Stock Price Prognosis for Next Days Walletinvestor.com AUTL Forecast, Long-Term Price Predictions for Next Months and Year: 2021, 2022 In the chart below, we can see that institutional . Investing.com U.K.-based biopharmaceutical firm Autolus Therapeutics Ltd (NASDAQ:AUTL) announced Monday that Blackstone (NYSE:BX) will invest as much as $250 million in the company to support . With a market capitalization of US$446m, Autolus Therapeutics is a small cap stock, so it might not be well known by many institutional investors. 6 equities research analysts have issued twelve-month price targets for Autolus Therapeutics' shares. Autolus Therapeutics Reports Second Quarter 2021 Financial Results and Operational Progress - Conference call to be held on August 5, 2021 at 8:30 am ET/1:30 pm BST - August 05, 2021 07:00 ET .
Winter Dragon Dragonvale, Modal Verbs And Modal Adverbs Examples, Computational Biology Cornell, Seaworld Killer Whale Show Times, Thermo Fisher Salary Bands,